Understanding Endothelial Corneal Transplant
The cornea is the clear, dome-shaped front surface of the eye that focuses light onto the retina. While it appears to be a single transparent layer, the cornea is composed of five distinct layers. The innermost layer, the corneal endothelium, is a thin sheet of specialized cells lining the back surface of the cornea.
Endothelial cells serve as a biological pump, constantly moving fluid out of the cornea to maintain its clarity. When functioning properly, they keep the cornea in a state of relative dehydration essential for clear vision. Unlike many other cells in the body, corneal endothelial cells do not regenerate in meaningful numbers once lost. The eye is born with a finite supply, and as cells are damaged or die off, the remaining cells stretch to cover the gaps left behind.
When the endothelial cell count drops below a critical threshold, the pump mechanism fails. Fluid seeps into the corneal tissue and causes swelling, a condition known as corneal edema. This swelling scatters incoming light and results in cloudy or blurred vision that worsens over time.
Several conditions can lead to endothelial cell loss and corneal swelling. The two most common reasons patients require endothelial transplant surgery are Fuchs endothelial dystrophy and pseudophakic bullous keratopathy.
Fuchs endothelial dystrophy is a slowly progressive, inherited condition in which endothelial cells gradually deteriorate over years or decades. In early stages, patients may notice foggy vision upon waking that clears as the day progresses, because fluid accumulates in the cornea overnight and evaporates during waking hours. As the disease advances, vision remains blurred throughout the day and small, painful blisters called epithelial bullae may form on the corneal surface.
Pseudophakic bullous keratopathy occurs when endothelial cells are damaged during or after cataract surgery or other intraocular procedures. Although modern surgical techniques have reduced this risk, some eyes experience enough cell loss to develop persistent corneal swelling. Other less common causes of endothelial failure include certain types of glaucoma, trauma, and inflammatory conditions affecting the inner corneal surfaces.
For much of the history of corneal transplantation, the standard treatment for endothelial failure was penetrating keratoplasty, in which the full thickness of the diseased cornea is removed and replaced with a donor cornea. While penetrating keratoplasty can restore clarity, it requires a large incision through all corneal layers and many sutures. This creates a prolonged recovery period and introduces risks of suture-related complications, high or irregular astigmatism, and wound vulnerability that can persist for years.
Endothelial keratoplasty techniques, including DSAEK and DMEK, take a fundamentally different approach. Rather than replacing the entire cornea, these procedures selectively replace only the damaged endothelial layer while leaving the patient's healthy corneal tissue intact. This targeted strategy offers meaningful advantages: smaller incisions, fewer or no sutures, faster visual recovery, a more stable eye structure, and reduced risk of graft rejection.
Who Is a Good Candidate
Patients diagnosed with Fuchs endothelial dystrophy who are experiencing visually significant corneal swelling are among the most common candidates for endothelial transplant surgery. The decision to proceed depends on how corneal clouding affects daily activities such as reading, driving, or working. In early stages, symptoms can often be managed with hypertonic saline drops or ointments that draw fluid out of the cornea. When these conservative measures no longer provide adequate relief, surgical intervention becomes the appropriate next step.
Individuals who develop persistent corneal swelling following cataract surgery or other intraocular procedures may benefit from endothelial transplant. In these cases, the corneal stroma is typically healthy, making partial-thickness transplant an ideal solution because only the damaged endothelial layer needs replacement. Preserving the remaining corneal architecture leads to better structural integrity and visual outcomes.
Some patients told they need a corneal transplant may assume that full-thickness penetrating keratoplasty is their only option. For those whose disease is limited to the endothelial layer, DSAEK or DMEK offers a less invasive path with a shorter recovery timeline. These patients benefit from learning about partial-thickness options and how the targeted approach can reduce downtime and improve visual results.
Patients who have both endothelial disease and cataracts can often undergo endothelial transplant combined with cataract surgery in a single session. This combined approach reduces the total number of surgeries, minimizes overall recovery time, and allows the surgeon to optimize the lens implant selection while addressing the corneal condition simultaneously.
How It Works
Endothelial keratoplasty replaces the dysfunctional endothelial cell layer with healthy donor tissue while preserving the patient's own corneal stroma and epithelium. The surgeon removes the diseased endothelial cells from the back surface of the cornea and introduces a thin disc of donor tissue through a small incision. This donor tissue is positioned against the back of the cornea and held in place by an air bubble injected into the front chamber of the eye. Over the following hours and days, the donor tissue adheres to the cornea, and the new endothelial cells begin pumping fluid out of the stroma, gradually restoring clarity.
DSAEK involves transplanting a thin disc of donor tissue that includes the endothelium, Descemet membrane, and a thin layer of posterior corneal stroma. The donor tissue is prepared using a microkeratome, which creates a smooth, uniform graft. The surgeon makes a small incision, removes the diseased endothelium, and inserts the donor tissue into the eye. An air bubble is placed beneath the graft to press it against the cornea.
The DSAEK graft is thicker than a DMEK graft, making it easier to handle and position during surgery. This can be advantageous in eyes with complex anatomy. The trade-off is that the additional stromal tissue can create a slight optical interface that may limit final visual acuity compared to DMEK.
DMEK involves transplanting only the endothelium and its basement membrane, Descemet membrane, without additional stromal tissue. This creates the thinnest possible graft, closely mimicking the eye's natural anatomy. The donor tissue is carefully peeled from the donor cornea and scrolled into a tight roll for insertion through a small incision. Once inside the eye, the surgeon uses air and fluid to unscroll the tissue and position it against the back surface of the cornea.
Because the DMEK graft contains no stromal tissue, the optical interface between donor and recipient cornea is virtually seamless. This translates into faster visual recovery and a higher likelihood of achieving excellent visual acuity. However, the ultra-thin tissue is more delicate and technically demanding to handle, requiring significant surgical experience.
Both DSAEK and DMEK rely on healthy donor corneal tissue obtained through eye banks, which screen, process, and evaluate each donor cornea before making it available for transplantation. The endothelial cell count is assessed to ensure it meets quality thresholds, as robust cell density gives the transplant the best chance of long-term function.
Types and Options
The choice between DSAEK and DMEK depends on the characteristics of the patient's eye, the underlying condition, and the surgeon's assessment of which technique will yield the best outcome. Both procedures replace the damaged endothelium, but they differ in graft thickness, surgical complexity, recovery speed, and visual outcomes.
Key distinctions include:
- Graft thickness: DSAEK grafts include a thin layer of stroma and are thicker overall, while DMEK grafts consist of only the endothelium and Descemet membrane
- Visual recovery: DMEK tends to produce faster visual improvement and a higher percentage of patients achieving 20/20 or near-20/20 vision
- Surgical handling: DSAEK grafts are easier to manipulate during surgery, while DMEK grafts require more advanced tissue-handling techniques
- Graft detachment rate: DMEK has a somewhat higher rate of early graft detachment requiring re-bubbling with air, though this is typically a minor additional procedure
- Rejection risk: Both procedures carry a lower risk of graft rejection compared to full-thickness transplant, with DMEK showing a slightly lower rejection rate than DSAEK
Ultra-thin DSAEK is a refinement of the standard DSAEK technique in which the donor graft is prepared to be thinner than a conventional DSAEK graft, though still thicker than a DMEK graft. This approach aims to combine the easier tissue handling of DSAEK with improved visual outcomes that more closely approach those achieved with DMEK. Ultra-thin DSAEK can be a good option for patients who would benefit from the advantages of a thinner graft but whose eyes may present technical challenges that make DMEK less feasible.
Endothelial keratoplasty is appropriate when corneal disease is limited to the endothelial layer and the overlying stroma remains relatively healthy. In cases where the stroma has developed significant scarring, thinning, or irregularity in addition to endothelial failure, full-thickness penetrating keratoplasty may still be the most appropriate option. The evaluation process determines which layers are affected and guides the surgeon toward the technique that provides the best visual result.
For patients with both endothelial disease and visually significant cataracts, performing endothelial keratoplasty and cataract extraction in a single procedure is a well-established approach. This combined surgery, sometimes called a triple procedure, reduces the need for a second operation and allows the surgeon to select an intraocular lens that accounts for expected corneal changes following transplant. Combining procedures can also help preserve endothelial cells by avoiding the stress of a separate future surgery.
Technology and Diagnostic Tools
Specular microscopy is a non-invasive imaging technique that allows the surgeon to visualize and count the endothelial cells on the back surface of the cornea. This tool provides critical information about cell density, cell size, and cell shape, all of which help determine the health of the endothelium and guide treatment decisions. Serial specular microscopy measurements over time can track the rate of endothelial cell loss and help establish the optimal timing for surgical intervention.
Corneal pachymetry measures the thickness of the cornea at various points across its surface. Because endothelial dysfunction causes swelling, increased corneal thickness is an important indicator of pump failure. Advanced corneal tomography systems create three-dimensional maps of the cornea's shape, thickness, and curvature, providing a comprehensive picture of how the disease affects the corneal structure. These measurements are essential for surgical planning and for monitoring the cornea after transplant.
Anterior segment optical coherence tomography, or AS-OCT, produces high-resolution cross-sectional images of the cornea and front portion of the eye. This imaging allows the surgeon to visualize individual corneal layers in fine detail, assess the degree of swelling, and evaluate graft position and attachment after surgery. AS-OCT is particularly valuable in the postoperative period for detecting early signs of graft detachment that may require intervention.
The slit-lamp examination remains a fundamental tool in evaluating corneal endothelial disease. Using a focused beam of light and high magnification, the cornea specialist can observe characteristic findings such as corneal guttae (small excrescences on Descemet membrane that are hallmarks of Fuchs dystrophy), corneal edema, epithelial bullae, and signs of inflammation. The slit lamp is also used during postoperative visits to monitor graft clarity, attachment, and overall health.
What to Expect
In the weeks leading up to surgery, the cornea specialist will perform a thorough evaluation that includes measurements of corneal thickness, endothelial cell counts, and detailed imaging of the eye's structures. If the procedure will be combined with cataract surgery, additional measurements will be taken to determine the appropriate intraocular lens power. Patients will receive specific instructions about medications, including which eye drops to begin using before surgery and whether any current medications need to be adjusted.
Endothelial keratoplasty is performed as an outpatient procedure under local anesthesia with sedation. The surgery generally takes between 45 minutes and one hour, depending on whether it is performed alone or combined with cataract surgery. After the donor tissue is positioned and the air bubble is placed, the patient will be asked to lie face-up for a period of time to help the graft adhere to the cornea.
During the first several days, patients use prescribed antibiotic and anti-inflammatory eye drops to prevent infection and control swelling. Vision is typically blurry during this period as the cornea begins to clear. Patients should avoid bending forward, heavy lifting, and sleeping on the side of the operated eye, as these positions can shift the air bubble and interfere with graft attachment. The surgeon will see the patient within the first day or two to check graft position and confirm the air bubble is functioning as intended.
As the cornea gradually clears over the first several weeks, many patients begin to notice meaningful improvement in their vision. DMEK patients often experience faster visual recovery than DSAEK patients, with some achieving functional vision within two to four weeks. DSAEK patients may take somewhat longer, with vision continuing to improve over one to three months. During this period, the surgeon will monitor the graft for proper attachment, signs of rejection, and endothelial cell health. Anti-inflammatory drops are typically continued for several months and gradually tapered according to the surgeon's protocol.
Endothelial keratoplasty has demonstrated strong long-term graft survival and visual outcomes, with studies showing that DMEK graft survival exceeds 90 percent at five years (American Academy of Ophthalmology, 2023). Most patients who undergo DSAEK or DMEK can expect the transplanted tissue to function well for many years. Ongoing follow-up visits allow the cornea specialist to track endothelial cell density over time and detect any early signs of graft failure or rejection, which can often be treated successfully if caught promptly. Patients will continue using a low-dose anti-inflammatory drop on a long-term basis to help protect the graft from rejection.
Your Journey at Washington Eye Institute
The journey begins with a comprehensive evaluation by a fellowship-trained cornea specialist with advanced expertise in corneal transplantation, including DSAEK, DMEK, and penetrating keratoplasty. During this visit, the specialist reviews symptoms and visual history, performs a detailed slit-lamp examination, and obtains corneal imaging and endothelial cell measurements. This assessment determines the extent of endothelial disease, identifies other eye conditions that may need attention, and establishes whether the patient is a candidate for partial-thickness transplant.
Once the diagnosis is confirmed and surgery is recommended, the cornea specialist develops a treatment plan tailored to each patient's needs. This includes selecting the most appropriate surgical technique (DSAEK, DMEK, or ultra-thin DSAEK), determining whether to combine the procedure with cataract surgery, and coordinating with the eye bank to secure high-quality donor tissue. The specialist explains the rationale behind each recommendation and ensures the patient understands what to expect.
On the day of surgery, the team at Washington Eye Institute provides attentive care throughout the procedure and recovery period. Following surgery, patients are seen at regular intervals to monitor graft attachment, corneal clearing, and visual improvement. The postoperative schedule typically includes visits within the first few days, at one week, one month, three months, and then at regular intervals over the first year and beyond. This structured follow-up helps ensure the best possible outcomes and allows for early detection of any complications.
The relationship between patient and cornea specialist extends well beyond the surgical procedure. Long-term monitoring of endothelial cell density, corneal thickness, and graft clarity is essential for maintaining the health of the transplanted tissue. The specialist provides guidance on protective measures, medication management, and recognizing warning signs of graft rejection: increased redness, sensitivity to light, decreased vision, and eye pain. With proper follow-up and care, endothelial transplant grafts can provide clear, comfortable vision for many years.
Preparing for Your Procedure
Before scheduling endothelial keratoplasty, the cornea specialist reviews the patient's medical history and current medications. Certain medications, particularly blood thinners, may need to be adjusted before surgery in coordination with the primary care provider. Active eye infections or significant inflammation must be treated and resolved before proceeding. Patients with other eye conditions such as glaucoma will have these factored into the surgical plan.
Preparing for endothelial keratoplasty means understanding and planning for the recovery period. Patients should arrange for transportation home on the day of surgery and have someone available to assist during the first day or two. The face-up positioning requirement in the hours following surgery is critical for graft attachment. Patients should plan to take time away from work and strenuous activities during the first one to two weeks, though many people with desk-based occupations can return to work within a week for DMEK and within one to two weeks for DSAEK.
Patients receive a detailed eye drop schedule before surgery, including antibiotic drops to start before the procedure and anti-inflammatory drops that continue for an extended period afterward. Having all prescribed medications filled and ready before surgery day helps ensure a smooth transition into the postoperative routine. The clinical team will demonstrate proper eye drop technique and provide written instructions for the drop schedule, which changes at specific intervals during recovery.
Endothelial keratoplasty offers excellent visual outcomes for most patients, though the speed and extent of recovery can vary depending on the technique used, the severity of the underlying disease, and individual healing characteristics. DMEK typically produces faster visual improvement and a greater likelihood of achieving excellent vision, while DSAEK provides reliable results with a slightly longer recovery timeline. The cornea specialist will discuss realistic expectations during the preoperative consultation, helping patients understand the typical timeline and what factors may influence their results.
Frequently Asked Questions
DSAEK and DMEK are partial-thickness transplant techniques that replace only the damaged endothelial layer on the back surface of the cornea. A full-thickness transplant, known as penetrating keratoplasty, removes and replaces all layers of the cornea. Partial-thickness procedures require smaller incisions, use fewer or no sutures, maintain more of the eye's natural structural strength, and typically result in faster visual recovery with less induced astigmatism. Full-thickness transplant remains appropriate when disease involves the entire cornea, but when the problem is isolated to the endothelium, DSAEK and DMEK offer a more targeted solution.
Visual recovery timelines differ between the two techniques. With DMEK, many patients notice significant improvement within two to four weeks, with vision continuing to refine over the following months. With DSAEK, meaningful improvement typically begins within one to three months, with continued refinement possible over three to six months. Factors such as the severity of preoperative swelling, other eye conditions, and individual healing rates can influence recovery speed. The cornea specialist provides guidance on expected timelines based on each patient's situation.
As with any surgical procedure, endothelial keratoplasty carries certain risks. The most common complication is partial or complete graft detachment in the early postoperative period, which may require a re-bubbling procedure in which additional air is placed beneath the graft. Other potential risks include graft rejection, infection, increased eye pressure, and gradual endothelial cell loss over time. The risk of rejection with partial-thickness techniques is lower than with full-thickness transplant. Most complications can be managed successfully when detected early through regular follow-up.
Endothelial transplant grafts provide long-lasting improvement in vision and corneal clarity, with studies showing strong graft survival rates extending well beyond ten years for both DSAEK and DMEK. Because the transplanted endothelial cells gradually decrease in number over time, some grafts may eventually require replacement. Regular monitoring of endothelial cell density helps the cornea specialist track graft health and anticipate future needs. Proper use of anti-rejection drops and adherence to the follow-up schedule are important factors in maximizing graft longevity.
Yes, endothelial keratoplasty is commonly combined with cataract surgery in patients who have both endothelial disease and visually significant cataracts. Performing both procedures in a single session offers fewer total surgeries, a single recovery period, and the ability to optimize intraocular lens selection while accounting for expected corneal changes after transplant. The cornea specialist determines whether a combined procedure is appropriate based on the severity of the cataract, endothelial condition, and other individual factors.
Graft rejection occurs when the body's immune system recognizes the donor tissue as foreign and mounts a response against it. Signs include increased redness, light sensitivity, decreased vision, and discomfort. If detected early, rejection episodes can often be treated successfully with intensive anti-inflammatory drops or other medications, allowing the graft to recover. In cases where a graft fails despite treatment, a repeat endothelial transplant can be performed using new donor tissue. The success rate of repeat transplants is generally favorable, and many patients achieve good visual outcomes after a second procedure.